Results 221 to 230 of about 134,252 (360)

Epomediol ameliorates pruritus in patients with intrahepatic cholestasis of pregnancy

open access: green, 1992
Manuel C. González   +8 more
openalex   +2 more sources

Development of Betalactam‐Predictor: A Clinical Decision Tool for Delabeling Low‐Risk Betalactam Allergy Patients. Initial Validation in Penicillin Allergy

open access: yesAllergy, EarlyView.
BL‐Predictor has emerged as a new tool for delabeling penicillin allergy. External validation has shown a specificity of 93% for detecting low‐risk patients. This score could potentially reduce diagnostic costs and the negative consequences associated with incorrect antibiotic allergy labels.
Marina Labella   +14 more
wiley   +1 more source

Temporal and external validation of the multidimensional scale—uremic pruritus in dialysis patients (UP‐Dial): A psychometric evaluation [PDF]

open access: bronze
Sirinda Jamjanya   +10 more
openalex   +1 more source

Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema

open access: yesAllergy, EarlyView.
This study performed an unbiased molecular profiling of CHE patients across diverse etiologies to identify shared pathogenic drivers and evaluate the impact of IL‐4Rα blockade via dupilumab over 16 weeks. CHE shows a mixed immune signature involving type 1, 2, and 3 pathways with features of atopic dermatitis and psoriasis.
Perrine Gery   +25 more
wiley   +1 more source

Dupilumab‐Associated Palmar Erythema Successfully Treated With Fluconazole

open access: yes
Australasian Journal of Dermatology, EarlyView.
Katina J. Selvaraj, Geoffrey Lee
wiley   +1 more source

A One‐Strength Dose Escalation Regimen for Birch Pollen SCIT Is Safe and Tolerable in Children, Adolescents, and Adults

open access: yesAllergy, EarlyView.
This study evaluated safety and tolerability of birch pollen SCIT during dose escalation with a new One‐Strength regimen (3 injections, Strength B) compared to the Standard regimen (7 injections, Strengths A and B) in patients aged 5–65 years. Safety and tolerability were comparable between the two regimens in adults, adolescents, and adolescents, as ...
Marek Jutel   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy